Cart
sales@molnova.com
BCM-599
CAS No. 1820763-99-2
BCM-599( BCM599 )
Catalog No. M12805 CAS No. 1820763-99-2
BCM-599 is an efficient HBV capsid assembly inhibitor with in vitro IC50 of 13 uM, shows synergistic inhibitory effects on decreasing viral concentration combined with lamivudine in vivo.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 873 | Get Quote |
|
| 50MG | 1782 | Get Quote |
|
| 100MG | 2250 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameBCM-599
-
NoteResearch use only, not for human use.
-
Brief DescriptionBCM-599 is an efficient HBV capsid assembly inhibitor with in vitro IC50 of 13 uM, shows synergistic inhibitory effects on decreasing viral concentration combined with lamivudine in vivo.
-
DescriptionBCM-599 is an efficient HBV capsid assembly inhibitor with in vitro IC50 of 13 uM, shows synergistic inhibitory effects on decreasing viral concentration combined with lamivudine in vivo.
-
In Vitro——
-
In Vivo——
-
SynonymsBCM599
-
PathwayMicrobiology/Virology
-
TargetHBV
-
RecptorHBV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1820763-99-2
-
Formula Weight342.151
-
Molecular FormulaC14H10Cl2FN3O2
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESFC1=CC=C(C(NCC(NC2=C(Cl)N=C(Cl)C=C2)=O)=O)C=C1
-
Chemical NameN-(2-((2,6-dichloropyridin-3-yl)amino)-2-oxoethyl)-4-fluorobenzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Cho MH, et al. J Viral Hepat. 2014 Dec;21(12):843-52.
molnova catalog
related products
-
Risedronate Sodium
Risedronate Sodium, a nitrogen-containing bisphosphonate, inhibits osteoclast-mediated bone resorption and modulates bone metabolism, used in the treatment of osteoporosis.
-
Bay 41-4109
A potent, non-nucleosidic inhibitor of HBV nucleocapsid maturation with IC50 of 0.05 uM.
-
Inarigivir ammonium
Inarigivir ammonium is a dinucleotide antiviral compound that significantly reduces HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir is an agonist of retinoic acid-inducible gene-I (RIG-I) that activates intracellular innate immunity.
